Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Angal S · 1 trial · 1 indication
The Tonsillopharyngitis Severity Score (TSS) scale consists of the following symptoms: throat pain, difficulty in swallowing, salivation, erythema and fever rated on a 4-point scale (0 = no symptom to 3 = significant symptom). Total score range from 0 - 15.
| Arm | Type | Description |
|---|---|---|
| Angal S (Arm A) | EXPERIMENTAL | Patients received Angal S, topical spray \[Menthol\], 0,5 mg + 2 mg (Sandoz d.d., Slovenia), administered as three to five consecutive presses on the actuator button, 6-10 times per day, for a maximum 4 days or until full illness resolution |
| ANTI-ANGIN® FORMULA (Arm B) | ACTIVE_COMPARATOR | Patients received ANTI-ANGIN® FORMULA, topical metered spray, 0,12 mg + 0,24 mg (LLC "Valeant", Russia) administered as three to five consecutive presses on the actuator button, 6-10 times per day, for a maximum 4 days or until full illness resolution |
| Name | Type | Description |
|---|---|---|
| Angal S, topical spray [Menthol] | DRUG | 0,5 mg + 2 mg (Sandoz d.d., Slovenia), administered as three to five consecutive presses on the actuator button, 6-10 times per day, for a maximum 4 days or until full illness resolution |
| ANTI-ANGIN® FORMULA, topical metered spray | DRUG | 0,12 mg + 0,24 mg (LLC "Valeant", Russia) administered as one to two consecutive presses on the actuator button, up to 6 times per day, , for a maximum 5 days or until full illness resolution |
Inclusion Criteria: * Voluntarily signed informed consent for participation in this clinical study; * 18 to 45 years old inclusive, male and female; * Diagnosed uncomplicated acute infectious and inflammatory diseases of the pharynx, accompanied by a sore throat; * Onset of first symptoms of the un...
Angal S is a small molecule drug developed by Novartis AG for the treatment of sore throat. It is intended for patients with uncomplicated acute infectious and inflammatory diseases of the pharynx accompanied by a sore throat. The drug is administered as a topical spray.
Angal S is developed by Novartis AG, a multinational pharmaceutical company listed on the stock exchange under the ticker NVS. The drug is being investigated for the treatment of sore throat and is currently in Phase 3 clinical development.
Angal S is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 3 clinical trial has been completed to evaluate its efficacy and safety in patients with sore throat.
Angal S has one completed Phase 3 clinical trial registered as NCT03095508. This study compared the efficacy and safety of Angal S topical spray with ANTI-ANGIN FORMULA topical metered spray in 229 patients with uncomplicated acute infectious and inflammatory diseases of the pharynx accompanied by a sore throat.
No, Angal S is not the same as ANTI-ANGIN FORMULA. In clinical trial NCT03095508, Angal S was compared against ANTI-ANGIN FORMULA as an active control. The trial was designed to assess the comparative efficacy and safety of the two topical sprays in treating sore throat.